19 completed, 7 unknown, 6 recruiting, 4 terminated. 43 Phase 2, 6 Phase 3, 5 Phase 1.
Follow Encephalomyelitis: new trials by email Literature Review of Encephalomyelitis trials Research Report on Encephalomyelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19-B Cell Depletion in PAIS-ME/CFS Patients Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID) | Phase 2 | Not yet recruiting | Charite University, Berlin, Germany | 38 | 2026-12-01 | 2026-07-24 |
| Low-Dose Naltrexone For ME/CFS: Dose-Finding Low-Dose Naltrexone, 1.5mg, Low-Dose Naltrexone, 3.0mg, Low-Dose Naltrexone, 4.5mg - Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 75 | 2026-11-01 | 2026-10-08 |
| Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Rituximab(Genetical Recombination), Placebo - Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | Phase 2 | Recruiting | National Center of Neurology and Psychiatry, Japan | 30 | 2025-04-09 | 2025-04-30 |
| A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine MVA-BN-WEV, Placebo - Encephalitis | Phase 2 | Active not recruiting | Bavarian Nordic | 411 | 2025-03-10 | 2025-10-01 |
| RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue LingZhi capsule - Chronic Fatigue Syndrome (CFS), Post-COVID ME/CFS | Phase 2 / Phase 3 | Recruiting | The University of Hong Kong | 130 | 2025-01-02 | 2026-09-21 |
| Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Lumbrokinase - Long Covid, Post-treatment Lyme Disease Syndrome | Phase 1 / Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 120 | 2024-10-09 | 2026-03-13 |
| LIFT: Life Improvement Trial Pyridostigmine, Low-Dose Naltrexone, Placebo - ME/CFS, Long COVID | Phase 2 | Recruiting | Brigham and Women's Hospital | 160 | 2024-09-10 | 2026-10-15 |
| Low-dose Naltrexone for Post-COVID Fatigue Syndrome Low-Dose Naltrexone, Placebo - Post-Viral Fatigue Syndrome | Phase 2 | Completed | Luis Nacul | 160 | 2024-01-15 | 2026-03-20 |
| Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation Pregabalin, Independent walking training, Placebo - Chronic Fatigue Syndrome, COVID-19, Long Haul | Phase 2 | Terminated | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 23 | 2023-10-24 | 2026-06-17 |
| Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome Vericiguat Oral Tablet - Post-COVID ME/CFS | Phase 2 | Active not recruiting | Charite University, Berlin, Germany | 104 | 2023-06-22 | 2026-01-28 |
| The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Floradapt Intensive GI, Placebo - ME/CFS, IBS - Irritable Bowel Syndrome | Phase 2 | Recruiting | Nova Southeastern University | 100 | 2022-12-20 | 2025-03-04 |
| Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1 - Venezuelan Equine Encephalomyelitis | Phase 2 | Not yet recruiting | U.S. Army Medical Research and Development Command | 500 | 2021-06-01 | 2021-02-16 |
| Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], placebo - Hypogonadism, Male, Fatigue Syndrome, Chronic | Phase 2 | Recruiting | Seattle Institute for Biomedical and Clinical Research | 240 | 2021-03-22 | 2026-06-22 |
| Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection Ruconest - Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder) | Phase 2 | Completed | IMMUNOe Research Centers | 40 | 2021-01-11 | 2025-08-11 |
| Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome NAC 900mg/day, NAC 3600mg/day, NAC 0mg/day (Placebo) - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 95 | 2020-09-01 | 2026-06-22 |
| The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Pyridostigmine Bromide, Placebo - Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome | Phase 2 | Completed | Brigham and Women's Hospital | 45 | 2020-01-14 | 2022-11-08 |
| Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments 5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream - Vestibulodynia, Temporomandibular Disorder | Phase 2 | Completed | Duke University | 209 | 2019-11-04 | 2026-03-19 |
| The Comeback Study Preprocessed thawed donor FMT, Preprocessed thawed autologous FMT - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Completed | University Hospital of North Norway | 80 | 2019-02-15 | 2024-02-23 |
| Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome CT38 - Myalgic Encephalomyelitis, Chronic Fatigue Syndrome | Phase 1 / Phase 2 | Completed | LUCINDA BATEMAN, MD | 17 | 2018-07-23 | 2020-05-12 |
| High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome Acupuncture, moxibustion, placebo - Chronic Fatigue Syndrome | Phase 2 | Unknown | Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust | 210 | 2016-11-01 | 2016-10-05 |
Showing 20 of 43. Sign in to see all of them.
Fatigue Syndrome, Chronic (36) · Fatigue (9) · Post-Acute COVID-19 Syndrome (6) · Fibromyalgia (4) · Encephalomyelitis, Venezuelan Equine (3) · Pain (3) · COVID-19 (2) · Chronic Pain (2) · Cognitive Dysfunction (2) · Encephalitis (2) · Encephalomyelitis, Eastern Equine (2) · Hypotension, Orthostatic (2) · Irritable Bowel Syndrome (2) · Alphavirus Infections (1) · Autonomic Nervous System Diseases (1)
Neuroinflammatory Diseases (43) · Nervous System Diseases (42) · Chronic Disease (36) · Disease Attributes (36) · Musculoskeletal Diseases (36) · Neuromuscular Diseases (36) · Pathologic Processes (36) · Pathological Conditions, Signs and Symptoms (36) · Muscular Diseases (35) · Infections (15) · RNA Virus Infections (14) · Virus Diseases (14) · Signs and Symptoms (12) · Brain Diseases (8)
Desiccation (3) · Naltrexone (3) · Rituximab (3) · Acupuncture Therapy (2) · Pyridostigmine Bromide (2) · Sodium Chloride (2) · 3,4-dihydroxyphenylserine aldolase (1) · Ascorbic Acid (1) · Clonidine (1) · Cognitive Behavioral Therapy (1) · Cyclophosphamide (1) · Droxidopa (1) · Drug Evaluation (1) · Duloxetine Hydrochloride (1) · Etanercept (1)
U.S. Army Medical Research and Development Command (6) · Haukeland University Hospital (5) · Brigham and Women's Hospital (2) · Charite University, Berlin, Germany (2) · Duke University (2) · Bavarian Nordic (1) · Chelsea Therapeutics (1) · Columbia University (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Hospital Vall d'Hebron (1) · Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust (1) · IMMUNOe Research Centers (1) · Icahn School of Medicine at Mount Sinai (1) · K-PAX Pharmaceuticals, Inc. (1) · LUCINDA BATEMAN, MD (1)
United States (24) · Norway (7) · Germany (2) · Spain (2) · Belgium (1) · Canada (1) · China (1) · Hong Kong (1) · Japan (1) · Netherlands (1) · Poland (1) · Sweden (1)
Anthony Cardile, DO (2) · David Systrom, MD (2) · Judith Bellmann-Strobl, MD (2) · Olav Mella, PhD, MD (2) · Robert Rivard, MD (2) · Alfred E Slonim, MD (1) · Anders Luts, MD, PhD (1) · Andrea Nackley, PhD (1) · Andrew Krystal, M.D. (1) · Anthony P Cardile, DO, MAJ (1) · Beata Tarnacka, Prof, Md, PhD (1) · Carlos A. Fierro, MD (1) · Charles W Lapp, M.D. (1) · Daphne Kos, PhD (1)
PMID 26132314, PMID 22039471, PMID 22871021, PMID 23959519, PMID 24493300, PMID 25287104, PMID 25386668, PMID 25660434, PMID 26212172, PMID 26357864, PMID 26438161, PMID 27149955, PMID 28265678, PMID 28494812, PMID 29202780, PMID 29284500, PMID 32411717, PMID 33516248, PMID 33899755, PMID 34539356, PMID 35526605, PMID 36269028, PMID 38740499, PMID 38858151, PMID 39697147, PMID 40315935, PMID 41281561, PMID 41558017, PMID 42857927, PMID 5063895
1UG3NS141843-01A1 (1), 2014 (1), R01HD096331 (1), R01NS116887 (1), R21AR053963 (1), R21NR010539 (1)